Shots:

• AstraZeneca to receive $11M up front in cash and Aridis common stock. & will also receive ~ $115M upon the achievement of development and commercial milestones along with royalties on net sales. Aridis received ~$30M funding for the P-III trial of suvratoxumab from the EU Commission's IMI
• Aridis obtains exclusive rights for the development and commercialization of suvratoxumab for all indications & plans to launch a P-III study in Q4’21
• AstraZeneca also becomes a shareholder of Aridis through the issuance of common stock & retains rights of the first negotiation for future licensing of suvratoxumab

  Ref: PR Newswire | Image: AstraZeneca